Journal of Personalized Medicine, Volume 14, Issue 1
2024 January - 126 articles
Cover Story: Treatment with leucovorin (folinic acid), a reduced form of folate, can improve autism spectrum disorder (ASD) symptoms in those positive for folate receptor alpha autoantibodies (FRAAs). To expand on previous research, we studied 110 patients in an ASD clinic who underwent FRAA testing and evaluation with the Social Responsiveness Scale (SRS) and Aberrant Behavior Checklist (ABC). Those positive for soluble folate-binding proteins (sFBPs) had more severe ASD symptoms, and higher binding FRAA titers were associated with greater ABC irritability. Treatment with leucovorin improved most SRS subscales with higher binding FRAA titers associated with greater response. Leucovorin treatment also improved ABC irritability. These results underscore the need for biomarkers to guide the treatment of folate pathways in ASD and suggest that leucovorin may be effective for children with ASD. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.